Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

Subjects:

Increasing the stimulus intensity, i.e. the number of spikes in a volley, decreases axonal transmission times and the latency of stimulus response. by Helmut Schmidt (248902)

Data_Sheet_5_Chemical Similarity of Co-occurring Trees Decreases With Precipitation and Temperature in North American Forests.CSV by Brian E. Sedio (10875330)

“…Variation in metabolite richness among communities was positively correlated with species richness, but variation in mean chemical similarity was not. Our results are consistent with the hypothesis that plant metabolomes play a more important role in community assembly in wetter and warmer climates, even at temperate latitudes, and suggest that metabolomic traits can provide unique insight to studies of trait-based community assembly.…”

Decreased Tbx2 expression in the AV myocardium of <i>Ezh2</i> mutant mice. by Li Chen (5749)

DICER protein expression is significantly decreased in the absence of MOV10 and FMRP. by Monica C. Lannom (11772729)

Overexpression of GRK2 and β-arrestin-2 decreases cell surface GPR3 expression. by Katie M. Lowther (427408)

“…Densitometric values for surface GPR3 was divided by densitometric values for total GPR3 and normalized to GAPDH to compare the amount of GPR3 at the surface vs. total GPR3 expression. (*) indicates a significant decrease in surface/total GPR3 expression as a result of GRK2 and β-arrestin-2 overexpression. …”

The VPS C846G mutation decreases the stability of VPS11 protein. by Jinglan Zhang (401545)

Number of pulmonary endothelial cells decreased upon infection and started to proliferate during resolution to restore their number by 15 dpi accompanied by decreased endothelial a... by Emilie Pollenus (10147748)